(VIANEWS) – Riot Blockchain (RIOT), Corcept Therapeutics Incorporated (CORT), Construction Partners (ROAD) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Riot Blockchain (RIOT)
93% sales growth and 8.06% return on equity
Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. The company operates through three segments: Bitcoin Mining, Data Center Hosting, and Engineering. It also provides co-location services for institutional-scale bitcoin mining companies; critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners; operation of data centers; and maintenance/management of computing capacity. In addition, the company engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; and electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial, and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.
Earnings Per Share
As for profitability, Riot Blockchain has a trailing twelve months EPS of $-0.28.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.06%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.3%, now sitting on 286.74M for the twelve trailing months.
Sales Growth
Riot Blockchain’s sales growth is 1.2% for the ongoing quarter and 93% for the next.
2. Corcept Therapeutics Incorporated (CORT)
35.4% sales growth and 21.91% return on equity
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Earnings Per Share
As for profitability, Corcept Therapeutics Incorporated has a trailing twelve months EPS of $1.05.
PE Ratio
Corcept Therapeutics Incorporated has a trailing twelve months price to earnings ratio of 28.73. Meaning, the purchaser of the share is investing $28.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.91%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 8% and a negative 14.3%, respectively.
3. Construction Partners (ROAD)
17.2% sales growth and 12.54% return on equity
Construction Partners, Inc., a civil infrastructure company, engages in the construction and maintenance of roadways across Alabama, Florida, Georgia, North Carolina, and South Carolina. The company, through its subsidiaries, provides various products and services to public and private infrastructure projects, with a focus on highways, roads, bridges, airports, and commercial and residential developments. It also engages in manufacturing and distributing hot mix asphalt (HMA) for internal use and sales to third parties in connection with construction projects; paving activities, including the construction of roadway base layers and application of asphalt pavement; site development, including the installation of utility and drainage systems; mining aggregates, such as sand and gravel that are used as raw materials in the production of HMA; and distributing liquid asphalt cement for internal use and sales to third parties in connection with HMA production. The company was formerly known as SunTx CPI Growth Company, Inc. and changed its name to Construction Partners, Inc. in September 2017. Construction Partners, Inc. was incorporated in 1999 and is headquartered in Dothan, Alabama.
Earnings Per Share
As for profitability, Construction Partners has a trailing twelve months EPS of $1.18.
PE Ratio
Construction Partners has a trailing twelve months price to earnings ratio of 45.59. Meaning, the purchaser of the share is investing $45.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.54%.
Yearly Top and Bottom Value
Construction Partners’s stock is valued at $53.80 at 01:22 EST, way below its 52-week high of $62.35 and way higher than its 52-week low of $27.96.
Sales Growth
Construction Partners’s sales growth for the next quarter is 17.2%.
Moving Average
Construction Partners’s value is under its 50-day moving average of $55.10 and way higher than its 200-day moving average of $45.69.
4. Globus Maritime Limited (GLBS)
13.6% sales growth and 3.04% return on equity
Globus Maritime Limited, an integrated dry bulk shipping company, provides marine transportation services worldwide. It owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargoes. As of March 31, 2022, the company's fleet included nine vessels with a total carrying capacity of 626,257 deadweight tonnage. It charters its vessels to operators, trading houses, shipping companies and producers, and government-owned entities. The company was incorporated in 2006 and is based in Athens, Greece. Globus Maritime Limited is a subsidiary of Firment Trading Limited.
Earnings Per Share
As for profitability, Globus Maritime Limited has a trailing twelve months EPS of $0.26.
PE Ratio
Globus Maritime Limited has a trailing twelve months price to earnings ratio of 8.73. Meaning, the purchaser of the share is investing $8.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.04%.
5. Amphastar Pharmaceuticals (AMPH)
11.2% sales growth and 25.34% return on equity
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Earnings Per Share
As for profitability, Amphastar Pharmaceuticals has a trailing twelve months EPS of $2.91.
PE Ratio
Amphastar Pharmaceuticals has a trailing twelve months price to earnings ratio of 14.55. Meaning, the purchaser of the share is investing $14.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.34%.
Moving Average
Amphastar Pharmaceuticals’s worth is above its 50-day moving average of $41.96 and way below its 200-day moving average of $49.48.
Volume
Today’s last reported volume for Amphastar Pharmaceuticals is 333907 which is 9.69% below its average volume of 369750.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22.7%, now sitting on 676.21M for the twelve trailing months.
6. FirstCash (FCFS)
9.3% sales growth and 11.91% return on equity
FirstCash Holdings, Inc, together with its subsidiaries, operates retail pawn stores in the United States, Mexico, and rest of Latin America. Its pawn stores lend money on the collateral of pledged personal property, including jewelry, electronics, tools, appliances, sporting goods, and musical instruments; and retails merchandise acquired through collateral forfeitures on forfeited pawn loans and over-the-counter purchases of merchandise directly from customers. The company is also involved in melting scrap jewelry, as well as sells gold, silver, and diamonds in commodity markets. As of December 31, 2021, it operated 1,081 stores in the United States and the District of Columbia; 1,656 stores in Mexico; 60 stores in Guatemala; 13 stores in El Salvador; and 15 stores in Colombia. The company was incorporated in 1988 and is headquartered in Fort Worth, Texas.
Earnings Per Share
As for profitability, FirstCash has a trailing twelve months EPS of $5.13.
PE Ratio
FirstCash has a trailing twelve months price to earnings ratio of 22.99. Meaning, the purchaser of the share is investing $22.99 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.91%.
Moving Average
FirstCash’s value is below its 50-day moving average of $122.03 and above its 200-day moving average of $111.10.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 16.4% and 12.8%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.7%, now sitting on 3.23B for the twelve trailing months.
